Novartis (NYSE:NVS) Plummets on Q4 Miss
Market News

Novartis (NYSE:NVS) Plummets on Q4 Miss

Story Highlights

Novartis shares are under pressure today after its fourth-quarter results fell short of expectations.

Novartis (NYSE:NVS) shares are trending nearly 3% lower in the early session today after the pharmaceutical company’s fourth-quarter results failed to impress investors. Despite rising by 8% year-over-year, revenue of $11.42 billion lagged expectations by $460 million. In sync, EPS of $1.53 came in lower than estimates by $0.12.

For the full year, net sales rose by 8%, and operating income increased by 23%. In Q4, the company’s sales growth was primarily driven by double-digit gains in Entresto, Kisqali, Kesimpta, and Pluvicto.

Following the spin-off of the Sandoz business, Novartis has transformed itself into a “Pure play innovative medicines business.” The company is now focused on the four core therapeutic areas of cardiovascular-renal-metabolic, immunology, neuroscience, and oncology. For Fiscal Year 2024, Novartis foresees net sales growth in the mid-single-digits. Further, core operating income is seen rising in the high-single-digits.

Novartis is also increasing its dividend by 3.1% to CHF 3.30 per share. A shareholder vote on the proposed dividend increase is slated for March 5.

Is NVS Stock a Good Buy?

Overall, the Street has a Moderate Buy consensus rating on Novartis, and the average NVS price target of $118.50 implies a nearly 10% potential upside in the stock. That’s after a nearly 20% rise in the company’s share price over the past year.

Read full Disclosure

Related Articles
TheFlySchrodinger announces expanded license agreement with Novartis
TheFlyMediciNova notified of settlement in Sanofi Novartis litigation
TheFlyNovartis price target lowered to CHF 100 from CHF 105 at Deutsche Bank
Go Ad-Free with Our App